Oxana Beskrovnaya - Dec 10, 2021 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role: Chief Scientific Officer
Signature: /s/ Richard Scalzo, Attorney-in-Fact
Stock symbol: DYN
Transactions as of: Dec 10, 2021
Transactions value $: $0
Form type: 4
Date filed: 12/14/2021, 03:19 PM
Previous filing: Sep 22, 2021
Next filing: Mar 14, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DYN	Common Stock	Award	$0	+36.5K	+204.67%	$0.00	54.4K	Dec 10, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DYN	Stock Option (right to buy)	Award	$0	+54.8K		$0.00	54.8K	Dec 10, 2021	Common Stock	54.8K	$13.12	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of shares of Common Stock issuable under 36,524 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2022.
F2	Includes 50,991 unvested RSUs. Each unvested RSU represents the right to receive one share of Common Stock upon vesting.
F3	This option was granted on December 10, 2021. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2025.